270 related articles for article (PubMed ID: 30288427)
1. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
Joyce VR; Sun H; Barnett PG; Bansback N; Griffin SC; Bayoumi AM; Anis AH; Sculpher M; Cameron W; Brown ST; Holodniy M; Owens DK
MDM Policy Pract; 2017; 2(2):2381468317716440. PubMed ID: 30288427
[No Abstract] [Full Text] [Related]
2. Mapping the PHQ-8 to EQ-5D, HUI3 and SF6D in patients with depression.
Abdin E; Chong SA; Seow E; Tan KB; Subramaniam M
BMC Psychiatry; 2021 Sep; 21(1):451. PubMed ID: 34517871
[TBL] [Abstract][Full Text] [Related]
3. Mapping the Beck Depression Inventory to the EQ-5D-3L in Patients with Depressive Disorders.
Grochtdreis T; Brettschneider C; Hajek A; Schierz K; Hoyer J; Koenig HH
J Ment Health Policy Econ; 2016 Jun; 19(2):79-89. PubMed ID: 27453455
[TBL] [Abstract][Full Text] [Related]
4. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
[TBL] [Abstract][Full Text] [Related]
5. Mapping EQ-5D utility scores from the PedsQL™ generic core scales.
Khan KA; Petrou S; Rivero-Arias O; Walters SJ; Boyle SE
Pharmacoeconomics; 2014 Jul; 32(7):693-706. PubMed ID: 24715604
[TBL] [Abstract][Full Text] [Related]
6. Development of algorithms to estimate EQ-5D and derive health utilities from WHOQOL-HIV Bref: a mapping study.
Castro R; De Boni RB; Perazzo H; Grinsztejn B; Veloso VG; Ribeiro-Alves M
Qual Life Res; 2020 Sep; 29(9):2497-2508. PubMed ID: 32451983
[TBL] [Abstract][Full Text] [Related]
7. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
Yang Q; Yu XX; Zhang W; Li H
Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
[TBL] [Abstract][Full Text] [Related]
8. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
Doble B; Lorgelly P
Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
[TBL] [Abstract][Full Text] [Related]
9. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
[TBL] [Abstract][Full Text] [Related]
10. Mapping functions for the PHQ-9 and GAD-7 to generate EQ-5D-3L for economic evaluation.
Mukuria C; Franklin M; Hinde S
Eur J Health Econ; 2024 Apr; ():. PubMed ID: 38664317
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
12. Mapping the COPD Assessment Test onto EQ-5D.
Hoyle CK; Tabberer M; Brooks J
Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
[TBL] [Abstract][Full Text] [Related]
13. Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland-Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data.
Madan J; Khan KA; Petrou S; Lamb SE
Pharmacoeconomics; 2017 May; 35(5):549-559. PubMed ID: 28063083
[TBL] [Abstract][Full Text] [Related]
14. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the HUI3 and the EQ-5D-3L in a nursing home setting.
Lung T; Howard K; Etherton-Beer C; Sim M; Lewin G; Arendts G
PLoS One; 2017; 12(2):e0172796. PubMed ID: 28234983
[TBL] [Abstract][Full Text] [Related]
16. Assessing the external validity of algorithms to estimate EQ-5D-3L from the WOMAC.
Kiadaliri AA; Englund M
Health Qual Life Outcomes; 2016 Oct; 14(1):141. PubMed ID: 27716347
[TBL] [Abstract][Full Text] [Related]
17. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
18. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms.
Woodcock F; Doble B;
Med Decis Making; 2018 Nov; 38(8):954-967. PubMed ID: 30226101
[TBL] [Abstract][Full Text] [Related]
19. Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index.
Shi Y; Thompson J; Walker AS; Paton NI; Cheung YB;
Health Qual Life Outcomes; 2019 May; 17(1):83. PubMed ID: 31077251
[TBL] [Abstract][Full Text] [Related]
20. Mapping analysis to predict EQ-5D-5 L utility values based on the Oxford Hip Score (OHS) and Oxford Knee Score (OKS) questionnaires in the Spanish population suffering from lower limb osteoarthritis.
Martín-Fernández J; Morey-Montalvo M; Tomás-García N; Martín-Ramos E; Muñoz-García JC; Polentinos-Castro E; Rodríguez-Martínez G; Arenaza JC; García-Pérez L; Magdalena-Armas L; Bilbao A
Health Qual Life Outcomes; 2020 Jun; 18(1):184. PubMed ID: 32539838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
